Compare JMIA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | AGIO |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2019 | 2013 |
| Metric | JMIA | AGIO |
|---|---|---|
| Price | $9.30 | $27.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $16.75 | ★ $36.63 |
| AVG Volume (30 Days) | ★ 3.4M | 881.5K |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $188,930,000.00 | $54,028,000.00 |
| Revenue This Year | $29.81 | $104.62 |
| Revenue Next Year | $16.58 | $125.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.80 | ★ 48.03 |
| 52 Week Low | $1.60 | $22.24 |
| 52 Week High | $14.72 | $46.00 |
| Indicator | JMIA | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 51.41 |
| Support Level | $10.44 | $26.05 |
| Resistance Level | $12.37 | $29.93 |
| Average True Range (ATR) | 0.81 | 1.23 |
| MACD | -0.37 | 0.07 |
| Stochastic Oscillator | 3.78 | 49.36 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.